×

Month: April 2017

Today, we bring you an interview with Dr. Marvin Formosa, director of the International Institute on Ageing of the United Nations, Malta (INIA). First, let's find out how the issue of population aging was first introduced into the agenda of the United Nations and why the UN body focused on aging is located in Malta....
The CRISPR system (Clustered Regularly Interspaced Short Palindromic Repeats) has exploded onto the biotech sector as a relatively simple, highly efficient, and fast method for precisely introducing breaks into genomic loci [1-2]. The realization that it is a prokaryotic acquired immune system, although less often mentioned, has been equally paradigm changing [3]. Ironically, it's the...
Computer brain
The battle against aging is not going to be an easy one, and it will likely require the most refined tools modern science has to offer. Among them, artificial intelligence may be one of the most promising and is being extensively used by biogerontology researchers such as Dr. Alex Zhavoronkov. Helping to drive progress in...
The new research work on senolytic drugs by Baar et al. uses a rationally designed molecule that selectively targets senescent cells in vivo, both in an accelerated aging mouse model, and in normally aged mice as well, with few if any side effects [1]. Senolytics are a new class of potential anti-aging drugs that function by...
Parkinson’s disease is one of the most well known of the neurodegenerative diseases. The symptoms include tremors and loss of motor control, which are caused by the loss of dopamine producing neurons in the brain. In fact, most of us lose these neurons as we age, but to a lesser degree. Parkinson's sufferers have a...
The biotechnology company PureTech are moving towards human clinical trials with a new therapy that may slow down the aging process and combat age-related disease. The company has licensed two new drug candidates, derivatives of the drug Rapamycin, from pharmaceutical giant Novartis. PureTech have recently announced a joint venture with Novartis called resTORbio and are...